Tonight Turing Pharmaceuticals announced price cuts to hospitals up to 50% off list price.
From the press release:
Turing Reduces Cost of Daraprim® (pyrimethamine)
Price cuts of up to 50 Percent for Hospitals, Improving Access & Affordability
“We pledge that no patient needing Daraprim will ever be denied access.”
Zug, Switzerland — November 24, 2015 — Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today unveiled significant price cuts for hospitals on Daraprim.
“Combined with our robust patient access programs, this is an important step in our commitment to ensure ready access to Daraprim at the lowest possible out-of-pocket cost for both hospitals and patients.” said Nancy Retzlaff Turing’s Chief Commercial Officer. “We pledge that no patient needing Daraprim will ever be denied access.”
Turing will provide:
- Reductions of up to 50 percent of list price for hospitals, which are the first to treat about 80 percent of patients with toxoplasmosis encephalitis — the most common form of toxoplasmosis in the United States.
- New, smaller bottles of 30 tablets for hospitals to make it easier to stock Daraprim as well as lower their carrying costs. We plan to make these available in early 2016.
- Sample starter packages at zero cost to ensure physicians treating patients in the community have free and immediate access to start therapy in emergency situations. We plan to make these available in early 2016.
Read the entire release here.